Weekly Analysts’ Ratings Updates for Shire (SHP)

Several brokerages have updated their recommendations and price targets on shares of Shire (LON: SHP) in the last few weeks:

  • 2/1/2018 – Shire is now covered by analysts at Barclays PLC. They set an “equal weight” rating on the stock.
  • 1/29/2018 – Shire had its “buy” rating reaffirmed by analysts at Investec. They now have a GBX 8,000 ($110.53) price target on the stock.
  • 1/29/2018 – Shire had its “buy” rating reaffirmed by analysts at Societe Generale. They now have a GBX 8,000 ($110.53) price target on the stock.
  • 1/22/2018 – Shire had its “equal weight” rating reaffirmed by analysts at Barclays PLC.
  • 1/16/2018 – Shire had its “outperform” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 4,700 ($64.94) price target on the stock.
  • 1/15/2018 – Shire had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 1/15/2018 – Shire had its “hold” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 4,100 ($56.65) price target on the stock.
  • 1/11/2018 – Shire had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,000 ($69.08) price target on the stock.
  • 1/10/2018 – Shire had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 1/5/2018 – Shire had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a GBX 5,500 ($75.99) price target on the stock.
  • 12/20/2017 – Shire was downgraded by analysts at Liberum Capital to a “hold” rating. They now have a GBX 4,100 ($56.65) price target on the stock, down previously from GBX 4,200 ($58.03).

Shares of Shire PLC (SHP) traded up GBX 122 ($1.69) during mid-day trading on Monday, hitting GBX 3,197 ($44.17). The stock had a trading volume of 3,830,000 shares, compared to its average volume of 2,750,000. Shire PLC has a 1 year low of GBX 3,034 ($41.92) and a 1 year high of GBX 5,067 ($70.01). The company has a market capitalization of $29,090.00 and a PE ratio of 2,517.32.

In other news, insider Dominic Blakemore bought 165 shares of Shire stock in a transaction dated Tuesday, December 19th. The shares were purchased at an average cost of GBX 3,790 ($52.36) per share, with a total value of £6,253.50 ($8,639.82).

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply